Skip to main content

Table 1 Patient characteristics according to TDT (< 400 and ≥ 400) (n = 231)

From: Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients

  All patients TDT < 400 TDT ≥ 400 p-value
n = 231 n = 138 n = 93
Age (mean ± SD) 69.7 ± 9.4 70.8 ± 9.2 68.2 ± 9.5 0.046
Sex (Male/Female) 146 (63.2%)/85 (37.8%) 100 (72.5%)/38 (27.5%) 46 (49.5%)/47 (50.5%) < 0.001
Smoking History (Ever/Never) 138 (59.7%)/93 (40.3%) 98 (71%)/40 (29%) 40 (43%)/53 (57%) < 0.001
Serum CEA (mean ± SD) 4.53 ± 2.7 4.7 ± 8.8 4.2 ± 8.7 0.624
Type of resection
 Segmentectomy 24 (10.4%) 12 (8.7%) 12 (12.9%) 0.428
 Lobectomy 206 (89.2%) 125 (90.6%) 81 (87.1%)  
 Pneumonectomy 1 (0.4%) 1 (0.7%) 0  
Pathological Stage
 IA1 49 (21.2%) 17 (12.3%) 32 (34.4%)  
 IA2 61 (26.4%) 34 (26.4%) 27 (29%)  
 IA3 20 (8.7%) 13 (9.4%) 7 (7.5%)  
 IB 46 (19.9%) 31 (22.5%) 15 (16.1%)  
 IIA 26 (11.2%) 21 (15.2%) 5 (5.4%)  
 IIB 16 (6.9%) 12 (8.7%) 4 (4.3%)  
 IIIA 13 (5.6%) 10 (7.2%) 3 (3.2%)  
Histological type
 Adenocarcinoma 163 (70.6%) 78 (56.5%) 84 (90.3%) < 0.001
 Squamous cell carcinoma 44 (19%) 38 (27.5%) 6 (6.5%)  
 Others 25 (10.8%) 22 (15.9%) 3 (3.2%)  
Solid component
 Pure solid/Mixed GGO 114 (49.4%)/117 (50.6%) 80 (57.8%)/58 (42.2%) 34 (36.6%)/59 (63.4%) < 0.001
Tumor doubling time (all component)
 Infinite 24 (10.4%)    
 range (median, excluding infinite) 19.14–30,417.42 (230.4)    
Tumor doubling time (solid component)
 Infinite 30 (13%)    
 range (median, excluding infinite) 10.73–15,393.04 (175.5)    
  1. TDT Tumor Doubling Time, SD Standard deviation